Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 Summary Global Market Direct's pharmaceuticals report, "Toyama Chemical Co., Ltd. - Product Pipeline Review - 2012" provides data on the Toyama Chemical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Toyama Chemical Co., Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Toyama Chemical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Toyama Chemical Co., Ltd. - Brief Toyama Chemical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Toyama Chemical Co., Ltd. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Toyama Chemical Co., Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Toyama Chemical Co., Ltd.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Toyama Chemical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Toyama Chemical Co., Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Toyama Chemical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Toyama Chemical Co., Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Toyama Chemical Co., Ltd. and identify potential opportunities in those areas.

1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012
Published on December 2012
Report Summary
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012
Summary
Global Market Direct's pharmaceuticals report, "Toyama Chemical Co., Ltd. - Product Pipeline Review - 2012" provides data on the
Toyama Chemical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline,
complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Toyama Chemical Co.,
Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Toyama Chemical Co., Ltd. and
industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Toyama Chemical Co., Ltd. - Brief Toyama Chemical Co., Ltd. overview including business description, key information and facts,
and its locations and subsidiaries.
- Review of current pipeline of Toyama Chemical Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Toyama Chemical Co., Ltd. with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Toyama Chemical Co., Ltd.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Toyama Chemical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Toyama Chemical Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Toyama Chemical Co., Ltd.'s R&D portfolio and develop key strategic
initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Toyama Chemical Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Toyama Chemical Co., Ltd. and identify potential opportunities in those areas.
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6

2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Toyama Chemical Co., Ltd. Snapshot 5
Toyama Chemical Co., Ltd. Overview 5
Key Information 5
Key Facts 5
Toyama Chemical Co., Ltd. ' Research and Development Overview 6
Key Therapeutic Areas 6
Toyama Chemical Co., Ltd. ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Pipeline Products ' Combination Treatment Modalities 10
Toyama Chemical Co., Ltd. ' Pipeline Products Glance 11
Toyama Chemical Co., Ltd. ' Late Stage Pipeline 11
Registration Filed Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
Toyama Chemical Co., Ltd. Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Toyama Chemical Co., Ltd. ' Early Stage Pipeline Products 15
Pre-Clinical Products/Combination Treatment Modalities 15
Toyama Chemical Co., Ltd. ' Drug Profiles 16
favipiravir 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
garenoxacin mesylate 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
iguratimod 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ozenoxacin 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
T-1106 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/6

3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
T-2307 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
T-5224 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
T-614 + Methotrexate 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
T-817MA 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Toyama Chemical Co., Ltd. ' Pipeline Products by Route of Administration 27
Toyama Chemical Co., Ltd. ' Pipeline Products By Mechanism of Action 28
Toyama Chemical Co., Ltd. ' Recent Pipeline Updates 30
Toyama Chemical Co., Ltd. - Dormant Projects 32
Toyama Chemical Co., Ltd. ' Company Statement 33
Toyama Chemical Co., Ltd. ' Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Toyama Chemical Co., Ltd., Recent Developments 35
Toyama Chemical Co., Ltd.- Press Release 35
Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of Age
For New Antibacterial Compound Ozenoxacin 35
Sep 11, 2012: Eisai To Launch Anti-Rheumatic Agent Careram 35
Jun 29, 2012: Eisai And Toyama Chemical Receive Approval To Market Anti-Rheumatic Agent Iguratimod In Japan 36
Mar 15, 2012: JPM-TMT Announces $138.5m Grant To MediVector For Development Of Influenza Drug, Favipiravir 37
Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo And
Other Infectious Dermatological Conditions 38
Mar 24, 2009: Toyama Chemical And Eisai Decide to Conduct Additional Study For Anti-Rheumatic Drug T-614 38
Financial Deals Landscape 39
Toyama Chemical Co., Ltd., Deals Summary 39
Toyama Chemical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 40
Licensing Agreements 40
Toyama Chemical Enters Into Licensing Agreement With Roche 40
Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical 42
Acquisition 44
Taisho Pharma Acquires Minority Stake In Toyama Chemical 44
FUJIFILM Holdings Acquires 66% Stake In Toyama Chemical 46
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/6

4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Expert Panel Validation 48
Contact Us 49
Disclaimer 49
List of Tables
Toyama Chemical Co., Ltd., Key Information 5
Toyama Chemical Co., Ltd., Key Facts 5
Toyama Chemical Co., Ltd. ' Pipeline by Indication, 2013 7
Toyama Chemical Co., Ltd. ' Pipeline by Stage of Development, 2013 8
Toyama Chemical Co., Ltd. ' Monotherapy Products in Pipeline, 2013 9
Toyama Chemical Co., Ltd. ' Combination Treatment Modalities in Pipeline, 2013 10
Toyama Chemical Co., Ltd. ' Filed, 2013 11
Toyama Chemical Co., Ltd. ' Phase III, 2013 12
Toyama Chemical Co., Ltd. ' Phase II, 2013 13
Toyama Chemical Co., Ltd. ' Phase I, 2013 14
Toyama Chemical Co., Ltd. ' Pre-Clinical, 2013 15
Toyama Chemical Co., Ltd. ' Pipeline By Route of Administration, 2013 27
Toyama Chemical Co., Ltd. ' Pipeline Products By Mechanism of Action, 2013 28
Toyama Chemical Co., Ltd. ' Recent Pipeline Updates, 2013 30
Toyama Chemical Co., Ltd. - Dormant Developmental Projects,2013 32
Toyama Chemical Co., Ltd., Other Locations 34
Toyama Chemical Co., Ltd., Subsidiaries 34
Toyama Chemical Co., Ltd., Deals Summary 39
Toyama Chemical Enters Into Licensing Agreement With Roche 40
Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical 42
Taisho Pharma Acquires Minority Stake In Toyama Chemical 44
FUJIFILM Holdings Acquires 66% Stake In Toyama Chemical 46
List of Figures
Toyama Chemical Co., Ltd. ' Pipeline by Indication, 2013 7
Toyama Chemical Co., Ltd. ' Pipeline by Stage of Development, 2013 8
Toyama Chemical Co., Ltd. ' Monotherapy Products in Pipeline, 2013 9
Toyama Chemical Co., Ltd. ' Combination Treatment Modalities in Pipeline, 2013 10
Toyama Chemical Co., Ltd. ' Pipeline By Route of Administration, 2013 27
Toyama Chemical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 28
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/6

5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 500.00 Quantity: _____
Site License--USD 3 000.00 Quantity: _____
Corporate License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/6

6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/6